|Bid||8.30 x 800|
|Ask||11.25 x 900|
|Day's Range||10.12 - 10.45|
|52 Week Range||6.95 - 26.95|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -77.42% and -62.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Scholar Rock Holding...
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have Read More...
Gilead Sciences, Inc. (NASDAQ: GILD ) announced a strategic collaboration Wednesday with Scholar Rock Holding Corp (NASDAQ: SRRK ). Although not strictly a nonalcoholic steatohepatitis, or NASH, deal, ...